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The global prevalence of metabolic syndrome (MetS) and its associated components 
(high fasting glucose, waist circumference, blood pressure, triglycerides, and low HDL) have 
increased over the past few decades. In addition, abnormal thyroid hormone levels have been 
found to manifest in a cascade of metabolic dysfunction, which may be linked to MetS in youth. 
PURPOSE: The purpose of the study is to investigate the association between MetS, its 
components, and markers of thyroid function in a nationally-representative sample of 
adolescents. METHODS: The National Health and Nutrition Examination Survey III (1988-
1994) collected data on the components of metabolic syndrome and thyroid function in 1,322 
adolescents aged 12-18.9 years (613 males and 709 females). Participants were grouped based on 
MetS status, number of MetS components, and markers of thyroid function using age- and sex-
specific reference values (including thyroid stimulating hormone (TSH), thyroxine (T4), 
antithyroid peroxidase antibody (TPOAb), and antithyroglobulin antibody (TgAb). Logistic 
models were used to predict the status of the thyroid markers (as high/low) from MetS status, 
controlling for age, sex, and race/ethnicity.  RESULTS: In males MetS prevalence was 6.1% 
(16.7% had at least 2 MetS components). In females, MetS prevalence was 4.8% (22% had at 
least 2 MetS components). Males with ≥2 MetS components had significantly higher odds of 
 
 
being TPOAb positive (OR = 7.9, 95%CI [1.7,36.8]) and were not likely to be TgAb positive 
(OR = 0.7 95%CI [0.1,6.4]). Females with ≥2 MetS components were 1.8 times more likely to be 
TPOAb positive (OR = 1.8 95%CI [0.5,6.5]) and 1.3 times more likely to be TgAb positive (OR 
= 1.3 95%CI [0.4-4.3]). In males, TG, WC, HDL-C, and DBP were significantly increased in the 
elevated TPOAb group (all P<0.05). No significant differences were observed in females. Odds 
ratios for MetS components were calculated according to TSH decile. Male subjects in the top 
decile of TSH had significantly higher odds of elevated TG; females were less likely to have 
increased BP (both P<0.05). Males in the bottom TSH decile were unlikely to present with 
elevated fasting glucose while females are unlikely to have elevated TG, WC, or fasting glucose 
(all P<0.05). CONCLUSION: Covert thyroid dysfunction often accompanies many components 
of MetS. Therefore, we encourage future researchers to investigate the clinical utility of restoring 
thyroid function as a component in the consolidation of treatment for MetS. The present study is 
unable to explain the effect of TPOAb on MetS, although we do believe there is a link. Research 
should be conducted on the biochemical processes in which TPOAb may influence MetS. 
Plausibly, the present study, and studies conducted prior to ours suggest a bidirectional 
relationship between MetS and thyroid dysfunction. 
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CHAPTER I: MARKERS OF CARDIOMETABOLIC RISK AND THYROID DYSFUNCTION 
IN U.S. ADOLESCENTS: NHANES III.   
 
Introduction 
The global prevalence of metabolic syndrome (MetS) and its associated comorbidities 
have increased at an alarming rate (Ford, Giles, & Mokdad, 2004). Ford et al. (2008) found the 
prevalence of metabolic syndrome in U.S. adolescents, ages 12-17 years, was approximately 
4.5% (∼1.1 million adolescents).  This condition is related to various morbidities, including 
Type II diabetes, cardiovascular disease, and a plethora of cancers, and impacts the renal, 
hepatic, skin, ocular, sleep, reproductive, and cardiovascular systems (Kaur, 2014). 
The hypothalamic-pituitary-thyroid axis regulates the synthesis and secretion of TSH and 
thyroid hormones (Braverman et al., 2012). Initially, thyrotropin-releasing hormone is 
synthesized by hypothalamic neurons and secreted into the hypothalamic-pituitary portal venous 
system. It is then carried through this system to the pituitary where it stimulates the synthesis and 
secretion of thyroid stimulating hormone (TSH). TSH the primary regulator of thyroid function, 
is a glycoprotein synthesized and secreted from the anterior pituitary gland. TSH binds its 
receptors in the thyroid gland, stimulating the synthesis and secretion of thyroxine (T4) and 
triiodothyronine (T3). Regulation of the thyroid hormones is further controlled using a negative 
feedback loop. 
In relation to autoimmune thyroid issues, two antibodies (antithyroglobulin antibodies 
and antithyroid peroxidase antibodies) are measured during the diagnostic stage of thyroid 
dysfunction. Thyroglobulin is a glycoprotein dimer secreted into the follicular lumen to serve as 
the matrix for the synthesis of T4 and T3, as well as the storage form of the hormones and 
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iodide. Thyroglobulin reenters the cell to be digested in lysosomes when T4 and T3 are needed, 
leading to the release of the hormones into the blood stream (Braverman et al., 2012). 
Antithyroglobulin antibodies suggest autoimmune hypothyroidism, yet their function is unclear. 
The primary use of antithyroglobulin antibodies (TgAb) testing is for patients with differentiated 
thyroid cancers as an adjunctive test to serum measurements and may be an independent detector 
of changes in tumor size.      
 Thyroid peroxidase (TPO) is a glycoprotein with a prosthetic heme I group. TPO 
catalyzes the oxidation of iodide which is essential for the incorporation of iodide onto tyrosine 
residues in thyroglobulin and coupling of the iodotyrosines to generate T4 and T3. Antithyroid 
peroxidase antibodies (TPOAb) show affinity for an immunodominant region of the TPO 
molecule. TPOAbs are detected in nearly 100% of individuals suffering from autoimmune 
hypothyroidism and 80% of individuals with Graves’ disease. 
Thyroid dysfunction is generally observed as one of two states. Hypothyroidism, a 
decrease in production and secretion of free thyroxine (fT4) and free triiodothyronine (fT3) 
accompanied by increased thyroid stimulating hormone (TSH) secretion. The opposing state 
thyrotoxicosis (or hyperthyroidism) presents with elevated serum concentrations of fT4, fT3, or 
both (Braverman & Cooper, 2012, pg 523 & 354). Canaris et al. (2000) found abnormal thyroid 
levels in 9.9% of adults not taking thyroid medications. During a state of dysfunction, thyroid 
hormones have a negative effect on cellular metabolism and processes. Delayed diagnosis of 
hypothyroidism in infants, children, and adolescents may impact skeletal growth and maturation, 
pubertal development, and adult height (Braverman et al., 2012; Srinivasan & Misra, 2015).    
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Waring et al. (2012), stated that thyroid dysfunction and MetS are the most common 
endocrine disorders with major overlap. Relatedly, abnormal thyroid hormone levels exacerbate 
a cascade of metabolic dysfunction leading to an aggravation of defined MetS components 
(Martínez-Sánchez, Alvarez, Fernø, Nogueiras, Diéguez, & López, 2014). Original studies, 
reviews, meta-analysis, etc. have been conducted on the associations of MetS and thyroid 
dysfunction in adults (Delitala et al., 2017; Iwen et al., 2013). Yet, few have looked at how these 
associations exist in youth. Furthermore, of the few studies conducted in the young, most have 
low levels of external validity (confounded by cultural differences).  
 Khatiwada et al. (2016), suggested the effects of concurrent MetS and thyroid 
dysfunction may compound risk of CVD. In 2015, a study of obese children found TSH levels 
did not differ within sexes dependent on the presence or absence of MetS, however, fT3 and fT4 
tended to be higher in boys with MetS than those without (Minami, Takaya, Takitani, Ishiro, 
Okasora, Niegawa, & Tamai, 2015). Furthermore, TSH in the normal range was positively 
associated with systolic blood pressure (SBP), non-HDL-C, and glucose levels in girls. Roos et 
al. (2007) found that in euthyroid adults, TSH was only associated with one MetS risk factor, 
triglycerides (TG), while there was a significant relationship between fT4 and waist 
circumference (WC), TG, high density lipoprotein (HDL-C), and fasting glucose.  
Acknowledging the aggregation of variables interacting within thyroid dysfunction and 
MetS, it is crucial that researchers and clinicians systematically address the question of how 
these pathologies manifest and their potential relationships in adolescents. Therefore, the aim of 
this study is to examine the associations of thyroid dysfunction and MetS in a nationally-
representative sample of U.S. adolescents. 
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Methods 
Sampling & Subjects 
This cross-sectional study utilized data collected from the Third National Health and 
Nutrition Examination Survey (NHANES III, 1988-1994). NHANES III utilized a stratified, 
multistage probability design resulting in a nationally representative sample of the total U.S. 
noninstitutionalized civilian population. Boys and girls aged 12-18.9 were included in the study 
and the final sample included 1322 subjects (613 males and 709 females) (Table 1). We excluded 
pregnant females, those with missing key variables for metabolic syndrome and thyroid function, 
and those that fasted for less than six hours prior to serum blood draws. 
Metabolic Components 
Jolliffe & Janssen’s (2007) definition of adolescent-specific MetS, designed in NHANES 
data, was used to categorize MetS and its components. In brief, this definition was created via 
LMS regression where MetS criteria were linked to adult National Cholesterol Education 
Program - Adult Treatment Panel III (ATP) criteria which included: high waist circumference 
(≥102 cm in men and 88 cm in women), elevated SBP (≥130 mmHg) or DBP (≥85 mmHg), a 
low HDL-C (<1.03 nmol/l in men and <1.30 nmol/l in women), high triglycerides (≥1.7 nmol/l), 
and elevated fasting glucose (≥ 5.6 nmol/l). Male and female SBP curves represented the 92nd 
and 93rd percentiles, respectively; DBP curves represented the 97th and 99th percentiles, 
respectively. HDL-C curves for males and females represented the 26th and 43rd percentiles, 
respectively. TG curves represented the 89th percentile in both sexes. MetS was stratified by sex 
and participants were categorized as individuals with 0 or 1 metabolic risk factors versus those 
with 2 or more metabolic risk factors. Due to the small sample size of usable adolescents, 
compounded by the small number of adolescents outside of the thyroid clinical range, we chose 
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to base some analyses on the presence of ≥2 MetS components instead of the conventional ≥3 
MetS components. 
Thyroid Variables 
For TSH and T4, participants were categorized according to age- and sex-specific 
reference values using definitions by Zurakowski et al. (1999). The NHANES III thyroid 
variable antithyroid microsomal antibody is also known as anti-thyroid peroxidase antibodies 
(Czarnocka, Ruf, Ferrand, Carayon, & Lissitzky, 1985). For TPOAb and TgAb cutpoints we 
utilized Hollowell et al. (2002) values. Using the hormone cutpoints outlined by Zurakowski, 
four categories were created, for each sex, including high TSH, low TSH, high T4, and low T4. 
Antithyroid antibodies were collected and analyzed in conjunction with thyroid hormones as they 
affect autoimmunity resulting in dysfunctional synthesis and secretion. For TPOAb, participants 
were categorized as normal TPOAb (<0.5 IU/ml) or high TPOAb (>0.5 IU/ml). TgAb was 
categorized as normal TgAb (<1.0 IU/ml) or high TgAb (>1.0 IU/ml). Ranges for TPOAb and 
TgAb categories were not stratified by sex or age since this is not supported within the literature.  
Measurement Protocols 
SBP and DBP were recorded as the average of 3-4 seated, resting measurements. Waist 
circumference was measured to the nearest 0.1 cm at the location the iliac crest meets the 
midaxillary line of the body. All serum blood measurements were taken after at least a 6 hour 
fast. Radioimmunoassay was used for the measurement of T4. TSH was measured using a 
chemiluminescent immunometric assay. Direct radioimmunoassay system measured antithyroid 
peroxidase antibodies and antithyroglobulin antibody using a highly purified, stable preparation 
of I-labeled thyroid peroxidase enzyme and I-labeled thyroglobulin, respectively. Assays were 
standardized against MRC (Medical Research Council). Cholesterol, TG, and HDL-C were 
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analyzed using a Hitachi 704 Analyzer (Boehringer Mannheim Diagnostics, Indianapolis, IN). 
Glucose was measured using the glucose hexokinase method. (Department of Health and Human 
Services. National Center for Health Statistics. NHANES III Reference Manual and Reports. 
Hyatsville, MD: Center for Disease Control and Prevention, 1996). 
Experimental Design 
 Three models were analyzed for each of the four thyroid variables. All models were 
grouped by metabolic health status (0-1 MetS Components or ≥2 MetS components). Model 1 
consisted of boys and girls controlling for sex, age, and race-ethnicity. Model 2 included boys 
alone and did not control for sex, age, or race-ethnicity. Model 3 included girls alone and did not 
control for sex, age, or race-ethnicity. To compare metabolic health status with TSH, T4, 
TPOAb, and TgAb categories, between-group analyses were conducted. All models analyzed 
participants in the top and bottom 10% of sex- and age-specific reference ranges against those in 
the middle 80%. Analysis of the top and bottom 10% of sex- and age specific reference ranges 
were used to increase subsample size and include individuals with sub-clinically dysfunctional 
thyroid hormone ranges. All models also analyzed participants by the normal, high, and low 
groups (TSH and T4). 
Statistical Analysis  
SPSS Version 21 (Armonk, New York) was used for data analysis. The complex sample 
design was accounted for in each analysis, utilizing the NHANES weight, stratification, and 
clustering. Descriptive statistics were used to ensure normal frequencies within datasets. Subjects 
with variables consisting of nil values, or codes suggesting unusable data were removed from 
analysis. 
 
7 
 
Results 
SBP, HDL-C, fasting glucose, thyroxine, and TPOAb were statistically different between 
sexes (Table 1). Age, WC, DBP, TG, TSH, and TgAb were not different between sexes (Table 
1). In males MetS prevalence was 6.1% according to the ATP III definition. Furthermore, 16.7% 
of males had at least 2 MetS risk factors. In females, the prevalence of MetS was 4.8%, while 
22% had at least 2 components of MetS. Descriptive statistics can be found in Table 1. Males 
with ≥2 MetS components had significantly higher odds of being TPOAb positive (OR = 7.9, 
95%CI [1.7,36.8]) and were not likely to be TgAb positive (OR = 0.7 95%CI [0.1,6.4]). Females 
with ≥2 MetS components were 1.8 times more likely to be TPOAb positive (OR = 1.8 95%CI 
[0.5,6.5]) and 1.3 times more likely to be TgAb positive (OR = 1.3 95%CI [0.4-4.3]). Odds of 
being antibody positive in males and females with ≥2 MetS components versus those with ≤1 
MetS components can be found in Table 3. The estimated marginal means were calculated to 
show differences between MetS components in subjects with elevated TPOAb and those within 
the acceptable range. In males, TG, WC, HDL-C, and DBP were significantly increased in the 
elevated TPOAb group (all P<0.05) (Table 4). No significant differences were observed in 
females (Table 5). Odds ratios for MetS components were calculated according to TSH decile. 
As shown in Figure 1, male subjects in the top decile of TSH had significantly higher odds of 
elevated TG; females were less likely to have increased BP (both P<0.05). Figure 2 shows the 
odds of increased cardiometabolic risk in subjects in the bottom decile of TSH. Males in the 
bottom TSH decile are unlikely to present with elevated fasting glucose while females are 
unlikely to have elevated TG, WC, or fasting glucose (all P<0.05). No significant results were 
found for T4 or TgAb. 
 
8 
 
Discussion 
The most important findings in the current study are related to the links between multiple 
MetS components and markers of thyroid function in a nationally representative sample of U.S. 
adolescents. We attempted to elucidate the relationship between antithyroid autoantibodies and 
the components of MetS in U.S. adolescents. Our analysis found a significant relation between 
participants in the bottom decile of TSH and fasting glucose level in males and females.  
The current study found four of the six components of MetS (TG, WC, HDL, and DBP) 
were significantly associated with increased TPOAb values in males. Prior studies have shown 
that elevated TPOAb may signal impending thyroid dysfunction, however, little is known about 
the direct mechanisms relating antithyroid autoantibodies to MetS components (Mehran, 
Amouzegar, Tohidi, Moayedi, & Azizi, 2014). Nikkilä & Kekki (1972), found that thyroid 
hormones influence regulation of production and removal of plasma TG. In thyrotoxicosis, mean 
plasma TG levels and average total TG turnover rate are elevated. The primary feature of TG 
metabolism in hypothyroidism is a decrease in removal efficiency leading to a moderate increase 
in TG concentration. Increased adiposity (associated with WC) in hypothyroidism is primarily 
caused by decreased energy expenditure (Bianco, Maia, Da Silva, & Christoffolete, 2005). The 
current study found an association between TSH and waist circumference in females-only, which 
may be explained by the small sample. According to Tan, Shiue, and Kung (1988), thyroid 
hormone significantly effects the activity of hepatic lipase (HL). The researchers found that 
overexpression of HL due to hyperthyroidism led to decreased HDL-C levels. HDL-C levels 
increased after 3-4 months of treatment on antithyroid drugs. Streetan, Anderson, Howland, 
Chiang, & Smulyan (1988), showed a significant rise in DBP occurs during the change from 
hyperthyroidism to hypothyroidism; a significant fall in DBP is noted when euthyroidism is 
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restored. Streetan et al., suggest hypothyroidism may lead to hypotension due to increased 
extracellular fluid volume and fluid retention. Furthermore, Streetan hypothesized that some 
individuals with hypotension may have undiagnosed hypothyroidism that can be managed with 
thyroxine replacement therapy.  
We found the odds of having elevated fasting glucose while being categorized in the 
bottom decile of TSH level is unlikely (males (OR = 0.1 95%CI [0.1-0.4], females OR = 0.1 
95%CI [0.1-0.7]). In agreement with our findings, prior studies have shown that upon the 
development of hyperthyroidism glucose turnover increases significantly (Marecek, & Feldman, 
1973; Okajima, & Ui, 1979). Furthermore, Okajima et al., suggest the effects of hyperthyroidism 
are similar to those of catecholamines in relation to metabolic alterations. In a separate study, 
Okajima et al. (1979), found endogenous insulin suppression did not decrease hyperthyroid 
induced increases in glucose turnover rates (while in a starved state). It is unlikely insulin action 
mediates thyroid-dependent stimulation of glucose turnover (glucose disposal rate constant) as 
insulin secretion is diminished and circulating insulin undergoes rapid breakdown (decreased 
insulin half-life) in hyperthyroidism (Renauld et al., 1971; Cavagnini et al., 1974; Orsetti et al., 
1974). Field et al. (1962), found evidence that TSH does not act by increasing glucose transport, 
instead it acts by increasing stimulation of glucose oxidation. 
Hunter et al. (2000), found a low prevalence of hypothyroidism in the young, however, 
values were at least twice those of previous estimates, “possibly indicating a rising incidence of 
autoimmunity in young people” (Hunter, Greene, MacDonald, & Morris, 2000). Isolated 
occurrences of MetS and thyroid dysfunction lead to various metabolic issues that increase in 
magnitude and mortality with age (Meng, Liu, Zhang, Liu, Song, Tan, & Ren, 2015). Minami et 
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al. (2015), hypothesized that involvement of thyroid function in the development of MetS might 
differ between children and adults.  
Strengths of the study include the nationally representative sampling and the uniqueness 
of researching thyroid variables and MetS components in American adolescents. The main 
limitation of the study is the cross-sectional methodology utilizing data from 1988-1994. 
Therefore, the study does not allow determination of causation. It must be acknowledged that 
when conducting a multivariate study including endocrine function, it is difficult to control for 
confounding variables. Future research should examine the influence of sex hormones on the 
associations of MetS and thyroid function. Research should also include long-term longitudinal 
studies examining the outcome of individuals in the top and bottom 10% of normal thyroid 
ranges. 
Conclusion 
 
 Covert thyroid dysfunction often accompanies many components of MetS. Therefore, we 
encourage future researchers to investigate the clinical utility of restoring thyroid function as a 
component in the consolidation of treatment for MetS. The present study is unable to explain the 
effect of TPOAb on MetS, although we do believe there is a link. Research should be conducted 
on the biochemical processes in which TPOAb may influence MetS. Plausibly, the present study 
and studies conducted prior to ours suggest a bidirectional relationship between MetS and 
thyroid dysfunction.  
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Table 1 
Characteristics of Subjects 
 Male Female Total 
N 
Age (yrs) 
Race-Ethnicity (%) 
            Non-Hispanic White 
            Non-Hispanic Black 
            Mexican American 
            Other 
Metabolic Syndrome (%) 
            Metabolic Syndrome Positive 
            ≥ 2 Metabolic Syndrome Components 
Waist Circumference (cm) 
*Systolic Blood Pressure (mm Hg) 
Diastolic Blood Pressure (mm Hg) 
*High Density Lipoprotein – Cholesterol 
(mmol/L) 
Triglycerides (mmol/L) 
*Fasting Glucose (mmol/L) 
*Thyroxine (nmol/L) 
            *High Thyroxine 
            * Low Thyroxine 
Thyroid Stimulating Hormone (mIU/L) 
             High TSH 
             Low TSH 
*Antithyroid Peroxidase Antibodies (%) 
>0.5 (IU/ml) 
Antithyroglobulin Antibody (%) 
>1.0 (IU/ml) 
613 
15.9 (0.1) 
 
69.1 (3.4) 
13.8 (1.7) 
9.1 (1.3) 
8.0 (2.4) 
 
6.1 
16.7 
77.8 (0.7) 
111.8 (0.5) 
61.9 (0.9) 
1.2 (0.1) 
 
1.0 (0.1) 
5.0 (0.1) 
110.0 (1.8) 
5.2 
0.6 
2.0 (0.2) 
3.5 
3.5 
2.8 (1.0) 
 
3.4 (1.3) 
709 
16.0 (0.1) 
 
64.1 (3.4) 
14.9 (1.8) 
8.0 (1.2) 
13.0 (3.0) 
 
4.8 
22.0 
76.9 (0.8) 
104.4 (0.6) 
61.1 (0.6) 
1.3 (0.1) 
 
1.0 (0.1) 
4.8 (0.1) 
117.1 (2.2) 
16.7 
3.1 
1.6 (0.1) 
2.7 
3.4 
6.9 (1.7) 
 
7.1 (1.5) 
1322 
15.9 (0.1) 
 
 
 
 
 
 
 
 
77.3 (0.5) 
108.0 (0.4) 
61.5 (0.6) 
1.3 (0.1) 
 
1.0 (0.1) 
4.9 (0.1) 
113.4 (1.6) 
 
 
1.8 (0.1) 
Data reported as means (standard error) or subsample (standard error); * Statistically 
significant between groups (P<0.05).           
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Table 2 
Odds of High/Low TSH and T4 Values by Metabolic Syndrome Components 
 
 
Male 
Odds Ratio 
[95%CI] 
Female 
Odds Ratio 
[95%CI] 
Combined 
Odds Ratio 
[95%CI] 
TSH  
 
 
 
  T4  
High Reference Range  
Top Decile  
Low Reference Range  
Bottom Decile  
High Reference Range  
Top Decile  
Low Reference Range  
Bottom Decile  
16.7[1.5-192.2] 
4.2[1.2-15.2] 
∞ 
0.2[0.1-0.9] 
1.3[0.3-5.4] 
1.7[0.6-4.7] 
1.4[0.3-6.3] 
0.6[0.2-2.4] 
1.4[0.3-7.0] 
0.8[0.2-2.5] 
0.1[0.03-0.5] 
0.2[0.1-0.6] 
1.1[0.5-2.5] 
0.8[0.3-2.2] 
0.6[0.1-3.0] 
0.9[0.3-2.3] 
5.0[1.4-18.2] 
1.8[0.7-4.8] 
0.1[0.002-0.3] 
0.2[0.1-0.5] 
1.2[0.5-2.6] 
1.2[0.5-2.8] 
0.6[0.2-1.8] 
0.8[0.4-1.9] 
Odds ratios compare males and females with ≥2 metabolic syndrome components against those 
with ≤1 metabolic syndrome components; Male and female odds ratios are unadjusted for sex, 
age, and race-ethnicity, Combined odds ratios are adjusted for sex, age, and race-ethnicity. 
 
 
 
 
 
Table 3 
Odds of Positive Antithyroid Antibodies by Metabolic Syndrome Components 
 
Male 
Odds Ratio 
[95%CI]  
Female 
Odds Ratio  
[95%CI]  
Male & Female   
       Odds Ratio 
          [95%CI]  
Antithyroid Peroxidase 
Antibody - Positive  
Antithyroglobulin Antibody 
- Positive  
7.9[1.7-36.8]  
0.7[0.1-6.4]  
1.8[0.5-6.5]  
1.3[0.4-4.3]  
2.6[1.1-6.7]  
1.1[0.3-3.3]  
Odds ratios compare males and females with ≥2 metabolic syndrome components against those 
with ≤1 metabolic syndrome components; Male and female odds ratios are unadjusted for sex, 
age, and race-ethnicity; Combined odds ratios are adjusted for sex, age, and race-ethnicity.  
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Table 4 
Male Antithyroid Peroxidase Antibody Estimated Marginal Means 
 ↑ Antithyroid Peroxidase 
Antibodies 
↔ Antithyroid Peroxidase 
Antibodies 
* Triglycerides 
† Waist Circumference 
‡ HDL 
Fasting Glucose 
Systolic Blood Pressure 
* Diastolic Blood Pressure 
1.3 
88.8 
1.1 
4.9 
115.0 
68.0 
0.9 
76.9 
1.3 
5.0 
110.6 
62.1 
* P<0.05, † P<0.01, ‡ P=0.001 
 
 
 
 
Table 5 
Female Antithyroid Peroxidase Antibody Estimated Marginal Means 
 ↑ Antithyroid Peroxidase 
Antibodies 
↔ Antithyroid Peroxidase 
Antibodies 
Triglycerides 
Waist Circumference 
HDL 
Fasting Glucose 
Systolic Blood Pressure 
Diastolic Blood Pressure 
1.1 
79.0 
1.4 
4.8 
104.4 
59.0 
0.961 
77.7 
1.4 
4.8 
107.5 
60.3 
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*P<0.05 
 
Figure 1. TSH top decile. 
 
 
 
 
 
 
*P<0.05 
 
Figure 2. TSH bottom decile. 
 
0
1
2
3
4
5
TG WC HDL Glucose BP
O
d
d
s 
R
at
io
Metabolic Syndrome Components
Male Female
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
TG WC HDL Glucose BP
O
d
d
s 
R
at
io
Metabolic Syndrome Components
Male Female
18 
 
CHAPTER II: EXTENDED REVIEW OF THE LITERATURE.  
 
Specific Research 
 This literature review aims to elucidate the controversial nature of research on MetS and 
thyroid function. To synthesize a balanced view of the current depth of investigation, the author 
presents research on the lack of consensus, development of current referent information, and 
etiology. Additionally, the known associations of MetS and thyroid function will be considered. 
It is well understood that obesity and lifestyle have strong influences on MetS, however, the 
pathogenesis remains unclear (Alberti, Eckel, Grundy, Zimmet, Cleeman, Donato, & Smith, 
2009). Slight disparities in establishment of diagnostic criteria may be explained by factors such 
as differences in analytical assays, ethnicity, and population or geographic covariates (Kapelari 
et al., 2008). 
In 1998, WHO proposed the first formalized MetS definition emphasizing insulin 
resistance as a required component for diagnosis. In 2001, the NCEP ATP III developed 
conflicting criteria; no single factor was integral, however, the presence of 3 of 5 factors was 
required. In 2005, the IDF dropped the requirement for insulin resistance and attempted to unify 
the clinical definitions of MetS with the AHA/NHLBI. The organizations came to a consensus 
on 4 of the 5 risk factors excluding assessment of abdominal obesity in the form of WC 
thresholds (related to insulin resistance).  
According to Alberti et al. (2009), establishing abdominal obesity values is difficult due 
to differences in relation to other MetS risk factors, predictive value of various levels of obesity 
on morbidity, and the difficulty of generating cut-points for continuous variables. The authors 
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went on to suggest that not only do ethnicities differ, but health systems require values unique to 
their circumstances rather than universal cut-points.  
 Compared with Europids, thresholds in the Asian population (e.g. China, Japan, India) 
should consist of lower values. The difference in MetS prevalence using high vs. low cut-points 
is minimal in the U.S. due to the significant correlation of abdominal obesity with MetS 
components and the high rates of obesity. 
 The IDF, AHA/NHLBI, World Heart Federation, International Atherosclerosis Society, 
and International Association for the Study of Obesity proposed a unified definition of criteria 
for the clinical diagnosis of MetS. The authors claim the definition recognizes the influence of 
demographics and encourages local groups to use their own discretion.  
 Currently, metabolic syndrome definitions are based on limited data. Large-scale 
longitudinal studies focusing on various race-ethnicities, ages, gender, and locals are required for 
the development of externally valid MetS definitions. Clinicians must use their experience, 
judgement, and knowledge of individual demographics when diagnosing MetS. 
 In 2007, Jolliffe & Janssen conducted a study with the purpose of developing age-specific 
adolescent MetS criteria linked to the NCEP ATP III and IDF adult criteria. The authors noted 
prior research for adolescent MetS definitions used arbitrary cut-points and determined the 
development of health-based criteria was necessary for use in clinical and research settings. 
 Jolliffe’s study used the MetS component cut-points developed with data from NHANES 
III, and continuous NHANES 1999-2002. Analysis consisted of 12-20 year old’s who had fasting 
measurements (≥6 hours as per NHANES protocol) of HDL-C, TG, and glucose. WC and BP 
were measured in all participants but analysis was limited to those who fasted, which resulted in 
2921 male and 3146 female participants.  
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To develop MetS cut-points, age- and sex-specific growth curves were developed using 
the Lambda Mu Sigma method (Cole & Green, 1992). MetS component growth curves were 
linked to the adult ATP and IDF cut-points (defined by the percentile that corresponded with the 
adult cut-point and regressed backward into adolescence). 
Jolliffe et al. found fasting glucose stayed constant (5.6 mmol/l) from ages 12-20 years. 
The study resulted in the development of MetS component cut-points at 1-year increments with 
each cut-point reflecting the midpoint of a given year. Alberti et al. reviewed the controversy 
between the IDF and ATP over WC values. Jolliffe and Janssen considered this controversy and 
developed growth curves for each organizations cut-points. The IDF MetS criteria assumes high 
WC for individuals with a BMI≥30 kg/m2, therefore, age- and sex-specific BMI cut-points were 
also created. The SBP and DBP curves were developed so they pass through 130 and 85 mmHg 
at 20.0 years of age. Male and female SBP curves represented the 92nd and 93rd percentiles, 
respectively; DBP curves represented the 97th and 99th percentiles, respectively. HDL-C cut-
points for males declined until age 16, while female cut-points increased after age 15. In males 
and females, HDL-C curves represented the 26th and 43rd percentiles, respectively. TG curves 
for males and females followed different trajectories, however, TG curves represented the 89th 
percentile in both genders.  
According to the ATP and IDF criteria, the study found a MetS prevalence of 7.6% and 
9.6% in adolescents, respectively. Prevalence did not differ by gender or age (p>0.2), however, 
IDF-MetS was lower in non-Hispanic blacks than non-Hispanic whites and Hispanics (p<0.05). 
The prevalence of MetS increased from NHANES III to continuous NHANES based on the 
adolescent criteria (ATP 4.7% to 7.6% and IDF 5.3% to 9.6%; p<0.01), which may be 
representative of increased obesity.  
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Overall, studies must be conducted to validate the adolescent MetS criteria developed in 
this study. The authors suggest using intermediate CVD and metabolic outcomes such as 
atherosclerotic lesions and endothelial function. The new adolescent criteria is based on health-
risk and reflects the changes in WC, BP, and lipoproteins that occur due to age. 
 Thyroid dysfunction is a controversial topic. Over the past 15 years, major debates on 
narrowing the accepted clinical values have persisted. The September 2005 issue of the Journal 
of Clinical Endocrinology & Metabolism published two contradictory articles. Wartofsky & 
Dickey (2005), claimed the accepted ranges for normal TSH levels were no longer valid and 
establishment of a true normal range for TSH was important. Alternatively, Surks, et al. (2005), 
conducted a study of 14,333 individuals using NHANES III data. Surks et al. stance was that 
levothyroxine treatment was not recommended for individuals in a subclinical hypothyroid state 
and that critical analysis of individuals in the upper reference range for TSH was lacking. The 
investigators concluded that the accepted reference ranges should remain unchanged. 
Subclinical hypothyroidism is defined as elevated serum TSH with normal fT4 and fT3 
levels. In 2002 the AACE, ATA, and TES cosponsored a Consensus Development Conference 
consisting of a panel of 13 experts meant to develop an evidence-based medicine approach to the 
unresolved clinical issues related to subclinical thyroid disease. Following the recommendations 
of the conference the leadership of the organizations determined there was not unanimous 
agreement by the three organizations on all conference recommendations.  
Subsequently, the organizations met again to review areas of disagreement. There was 
significant disagreement on routine treatment of patients with serum TSH level of 4.5-10 mU/l. 
Post review, each organization made additional recommendations and eventually endorsed a 
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final draft. The authors suggest hypothyroidism is on a continuum from subclinical, to overt, to 
life-threatening myxedema coma (Gharib et al., 2005).  
Mirroring other expert opinions, the review panel state that the provider’s clinical 
judgement is more critical than guidelines for routine screening. Furthermore, the review panel 
suggest the use of antithyroid antibodies is useful at predicting risk of developing overt 
hypothyroidism. In contrast, the consensus conference determined the evidence was insufficient 
to impose this recommendation. In agreement with the AACE, Royal College of Physicians, and 
ATA, the review panel endorsed the use of TPOAb for the management of thyroid dysfunction. 
The consensus panel recommendations were against treatment of subclinical hypothyroidism at 
TSH levels of 4.5-10 mU/l, however, the review panel claimed that separating the mildest 
disease for analysis (TSH of 5-10 mU/l) would increase difficulty of advocating for intervention 
because morbidity and mortality would be years away. According to the review panel, those in 
the controversial range of 4.5-10 mU/l should be considered for treatment (dependent on the 
clinician’s judgement). Current evidence suggests patients with TSH>10 mU/l should receive 
treatment (Gharib et al., 2005).  
In relation to subclinical hyperthyroidism, both the consensus conference and review 
panel believe patients with TSH suppression (0.1-0.4 mU/l) should be monitored while patients 
with complete TSH suppression (<0.1 mU/l) should be treated. 
In conclusion, endocrinologist advocating for narrowing the thyroid reference ranges 
suggest the side effects of early diagnosis and treatment are minor in respect to the possibility of 
undiagnosed thyroid dysfunction (Gharib, 2005). Furthermore, large, longitudinal studies in 
multiple demographics are required to provide sufficient data for the development of evidence-
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based guidelines. Gharib et al., suggest that experience and judgement, as well as flexibility 
within the current recommendations will facilitate clinicians and researchers in decision-making. 
Kapaleri et al. (2008) conducted a study with the aim of establishing age-specific 
reference intervals for serum TSH, fT3, and fT4 in healthy children, assess sex differences in 
thyroid function, and compare their results with previously published reference data.  
The investigators routinely collected results of serum TSH, fT3, and fT4 from a hospital 
based population of children aged 1 day - 18 years. 2,194 serum samples were collected and 
subjects were sub-grouped according to age (1 day-1 month, 1-12 months, 1-5, 6-10, 11-14, and 
15-18 years, respectively). Patients with eating disorders, pituitary disease, or chromosomal 
anomalies were excluded from analysis. Children with conditions or medications likely to affect 
thyroid function were excluded from the reference group. Patients were classified using the 
International Classification of Diseases code and each diagnostic group was statistically 
evaluated in comparison to Z00.0. Serum samples from patients having diagnostic codes 
suggesting thyroid dysfunction were excluded a-priori.  
Thyroid hormones were analyzed on an automated immunoassay using a direct 
chemiluminescence detection system. TSH, fT3, and fT4 values of each diagnostic group were 
compared to the sub-group of primarily healthy children; groups that were not statistically 
different were pooled with the healthy reference group. Comparison between age groups was 
conducted using unifactorial ANOVA with Tukey’s test post-hoc. Mean values between age 
groups and sexes were assessed using the student’s t-test. Medians and Percentiles (2.5th to 
97.5th) for each variable became the reference interval. 
The TSH sample size was 1,209; no difference was found between serum TSH 
concentrations at any age in male and female children (p = 0.689). Both sexes were combined for 
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calculation of percentiles. TSH values decreased and variance narrowed with increasing age. The 
fT3 sample was 1,395; values showed continuous decline after age 1 month (except in boys 1-5 
years and girls 6-10 years). Mean fT3 values for males were elevated in comparison to females 
(p < 0.001). The sample size for fT4 was 1229; no sex differences were found at any age group. 
fT4 levels were found to decline and narrow in variance with age.  
Despite the development of new techniques for determining free thyroid hormone values, 
the researchers assert it is still useful to use immunoassay procedures. The variable sensitivity of 
different measurement techniques and methodology must be taken into account when researchers 
and clinicians decide which reference values to use. Although it is common practice, the 
researchers acknowledged the use of a hospital-based population might confound reference 
values.  
In the end, the values developed in this study slightly differed when compared to previous 
studies. The authors concluded that further studies need to be conducted in children and 
adolescents to determine the significance sex has on thyroid hormone levels. Furthermore, the 
presence of TPOAb should be taken into account when determining thyroid function and 
reference intervals (Ladenson, Singer, Ain, Bagchi, Bigos, Levy, & Daniels, 2000; Cooper, 
2001).  
Roos et al. (2007), conducted a study with the aim of investigating the relationship 
between thyroid function, insulin resistance, and components of MetS in a large euthyroid 
sample. 1581 individuals ages 28-75 years, from the PREVEND study in Groningen, 
Netherlands were included. Subjects with thyroid dysfunction, diabetes, and those using thyroid 
medication, insulin, or oral blood glucose-lowering medications were excluded from the study. 
MetS was defined according to the ATP III and IDF criteria. Euthyroidism was defined as TSH 
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and fT4 within the normal reference range (0.35-4.94 mIU/l and 9.14-23.81 pmol/l, 
respectively). 
            Laboratory methods included the assessment of serum TSH, fT4, fT3, and insulin 
concentrations using a microparticle enzyme immunoassay. Serum TGs were measured 
enzymatically. Serum total cholesterol and plasma glucose were assessed using Kodak Ektachem 
dry chemistry. HDL-C was measured with a homogenous method while LDL-C was calculated 
using the Friedewald-formula. Serum Apo B and Apo A-I were determined using nephelometry. 
Multiple linear regression models were performed for associations of thyroid function with MetS 
components. 
            The investigators found the metabolic parameters of individuals with HOMA-IR and fT4 
in the lowest tertile were significantly different from those in the highest HOMA-IR tertile. fT4 
and fT3 were significantly higher in men than women (both P < 0.001). TSH was significantly 
lower in men than women (P = 0.006). TSH was positively associated with HDL-C, TG, and 
Apo-I. fT4 was negatively associated with total cholesterol, LDL-C, and TG. fT3 was negatively 
associated with total cholesterol, LDL-C, TG, and Apo B. When controlling for insulin 
resistance the relation between fT4 and BP became significant whereas, the relation with fasting 
glucose was no longer significant. 
            Overall, the authors concluded that individuals in the low normal thyroid range were 
already at an increased cardiovascular risk. Findings from the current study suggest fT4 and fT3 
in the normal range are related to cardiovascular risk rather than TSH. This may be explained by 
the difference in the effects thyroid hormones have on peripheral tissues versus central feedback 
inhibition of TSH release. Age and gender were shown to have significant correlations with 
components of MetS and thyroid hormones. Adjustments for insulin resistance weakened some 
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associations; however, all associations remained significant. Surprisingly, adjustment for obesity 
did not significantly change any associations. 
 Minami et al. (2015) conducted a study on 283 obese Japanese children aged 6-15 years. 
The study took place from 2009-2012 at the clinic for obese children at the Department of 
Pediatrics of Osaka Medical College Hospital. Blood samples and anthropometric measurements 
(including height weight, and WC) were taken the morning after an overnight fast; strenuous 
exercise was forbidden the day prior. Subjects were free of endocrine, metabolic, and renal 
diseases as well as conditions other than obesity. Obesity was defined as body weight>120% of 
standard body weight based on height and age norms for Japanese schoolchildren in 2000.  
 WC was measured to the nearest millimeter at umbilicus level. BP was measured three 
times consecutively using an automated sphygmomanometer (the third measurement was used 
for analysis). Comparison of obesity was evaluated using BMI-SDS. BMI- and height-SDS were 
calculated by dividing BMI or height by the 50th percentile for age and sex, respectively. Body 
composition was estimated by determining body fat percentage using BIA. 
 Blood samples of serum total cholesterol, TG, alanine aminotransferase (ALT), glucose, 
and uric acid were obtained using the AU5800 automated analyzer after an overnight fast. HDL-
C and LDL-C were quantified using an enzymatic method. Insulin, TSH, fT4, and fT3 were 
quantified using an electrochemiluminescence immunoassay. TSH, fT4, and fT3 reference 
ranges were 0.5–5.0 µIU/ml, 0.9–1.7 ng/dl, and 2.3–4.3 pg/ml, respectively. Insulin resistance 
was quantified using HOMA-R and QUICKI was calculated. The researchers used a MetS 
definition of WC≥75 cm (<13 years old) or WC≥80 cm (≥13 years old) or waist-to-height 
ratio≥0.5; TG≥120 mg/dl, and/or HDL≤40 mg/dl; SBP ≥125 mmHg and/or DBP≥70 mmHg; 
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and/or fasting plasma glucose≥100 mg/dl. Categorization as MetS positive required a high WC 
and two to three positive risk factors (dyslipidemia, hyperglycemia, and hypertension). 
Subject evaluation found height-SDS, WC, body fat percentage, ALT, and fT4 were 
higher in boys than girls, whereas TG levels were higher in girls than boys. Elevated serum TSH 
was found in 19.2% of boys and 19.6% of girls. In relation to QUICKI, obese boys with TSH≥4 
µU/ml differed from those with TSH<4 µU/ml. Obese girls with TSH≥4 µU/ml had higher non-
HDL-C and LDL-C at a younger age compared to those with TSH<4 µU/ml. fT3/fT4 was 
negatively correlated with QUICKI while TSH, fT3, and fT4 were not correlated with any 
variables. In contrast, for obese girls all hormone levels and fT3/fT4 were negatively correlated 
with age, while TSH was positively correlated with levels of glucose, DBP, and non-HDL-C in 
accordance with prior studies (Gierach, Gierach, & Junik, 2014; Chen, Xi, Zhang, Song,Liu, 
Mao, & Wang, 2012). Minami et al. found that age and values of height-SDS, WC, SBP, DBP, 
glucose, insulin, QUICKI, fT3/fT4 and uric acid were higher in obese boys with MetS than those 
without MetS. In obese girls, BMI-SDS, WC, SBP, DBP, insulin, QUICKI, non-HDL-C, and 
uric acid were higher when MetS was present.  
It is well established that insulin resistance is associated with obesity and metabolic 
syndrome (DeFronzo & Ferrannini, 1991). Furthermore, insulin resistance is positively 
associated with thyroid hormones within the normal range (Lambadiari, Mitrou, Maratou, Raptis, 
Tountas, Raptis, & Dimitriadis, 2011). Therefore, the interactions between these variables may 
culminate in hypothyroidism associated with insulin resistance progressing into metabolic 
syndrome (Guo, 2014; Kadiyala, Peter, & Okosieme, 2010). 
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Summary 
 In summation, there is a major debate between endocrinologists and researchers in 
relation to the diagnosis and treatment of MetS and thyroid dysfunction. Organizations such as 
the IDF, AHA/NHLBI, World Heart Federation, International Atherosclerosis Society, and 
International Association for the Study of Obesity have attempted to make a unified definition of 
MetS that accounts for variables such as geography, race, age, etc. Organizations such as the 
AACE, ATA, and TES believe treatment of subclinical thyroid dysfunction is unnecessary and 
may be harmful in certain cases. Alternatively, research has shown that treatment of undiagnosed 
hypothyroidism can improve individual components of MetS (Streetan et al., 1988). 
Investigation into the associations and mechanisms of thyroid dysfunction and MetS in the 
developing adolescent should continue. 
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